Keytruda and Etoposide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Keytruda (pembrolizumab) and Etoposide (etoposide). Common drug interactions include hepatitis among females and drug ineffective among males.

The phase IV clinical study analyzes what interactions people have when they take Keytruda and Etoposide. It is created by eHealthMe based on reports of 64 people who take the same drugs from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Etoposide?

Etoposide has active ingredients of etoposide. eHealthMe is studying from 77,815 Etoposide users. Check the latest studies of Etoposide.

On Aug, 11, 2026

64 people who take Keytruda and Etoposide together, and have interactions are studied.

Keytruda and Etoposide drug interactions.

What are the common drug interactions of Keytruda and Etoposide, by gender? *:

female:

Hepatitis (inflammation of the liver)
Nausea (feeling of having an urge to vomit)
Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
Anaphylactic reaction (serious allergic reaction)
Cardiomyopathy (weakening of the heart muscle)
Type i hypersensitivity
Neutropenia (an abnormally low number of neutrophils)
Peripheral motor neuropathy (muscles in the body become progressively weaker over months to years)
Peripheral sensory neuropathy (damage to one or more of your peripheral nerves)
Thrombocytopenia (decrease of platelets in blood)

male:

Drug ineffective
Meningitis aseptic (a condition that causes the membranes covering your brain and spinal cord to become inflamed)
Acute respiratory failure
Bronchial disorder
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs)
Fatigue (feeling of tiredness)
Full blood count decreased
Hypoaesthesia (reduced sense of touch or sensation)
Ill-defined disorder
Intestinal perforation (complete penetration of the wall of the intestine)

What are the common drug interactions of Keytruda and Etoposide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Death

10-19:

n/a

20-29:

Drug ineffective

30-39:

Hepatitis (inflammation of the liver)
Disease progression
Drug ineffective
Nausea (feeling of having an urge to vomit)
Neutropenia (an abnormally low number of neutrophils)
Peripheral motor neuropathy (muscles in the body become progressively weaker over months to years)
Peripheral sensory neuropathy (damage to one or more of your peripheral nerves)
Thrombocytopenia (decrease of platelets in blood)
Hyperthyroidism (over activity of the thyroid gland)
Thyroiditis (inflammation of thyroid gland)

40-49:

Type i hypersensitivity
Drug ineffective

50-59:

Myelosuppression (a decrease in the production of blood cells)
Productive cough
Pyrexia (fever)
Rash maculo-papular (red area on the skin that is covered with small confluent bumps)
Rash pruritic (redness with itching)

60+:

Meningitis aseptic (a condition that causes the membranes covering your brain and spinal cord to become inflamed)
Myasthenia gravis (a chronic condition that causes muscles to tire and weaken easily)
Rheumatoid arthritis (a chronic progressive disease causing inflammation in the joints)
Abdominal mass (localized enlargement or swelling in the human abdomen)
Acute respiratory failure
Death
Drug ineffective
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs)
Full blood count decreased
Hypoaesthesia (reduced sense of touch or sensation)

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 9 people, 14.06%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 6 people, 9.38%
Prostatic Adenoma (prostatic non-cancerous tumour): 4 people, 6.25%
Lung Cancer - Small Cell (lung cancer): 4 people, 6.25%
Chronic Myelomonocytic Leukaemia (cancers of the blood-forming cells of the bone marrow): 4 people, 6.25%
Bladder Cancer: 4 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and Etoposide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously